Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

Core Insights - Acumen Pharmaceuticals announced positive topline results from its Phase 1 study of sabirnetug, indicating that subcutaneous administration is well-tolerated and supports further clinical development [1][2] - The company emphasizes the potential for increased patient convenience with the subcutaneous formulation compared to intravenous treatment [2] - Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of soluble amyloid beta oligomers (AβOs) in Alzheimer's disease patients [3][5] Clinical Study Details - The Phase 1 study involved 12 healthy volunteers receiving single intravenous doses of 2,800 mg and 16 subjects receiving four weekly subcutaneous doses of 1,200 mg [2] - The most common adverse events were mild injection site reactions, occurring in 62.5% of subjects, with no significant safety concerns identified [2] - The ongoing Phase 2 ALTITUDE-AD study is evaluating the efficacy and safety of sabirnetug in patients with early Alzheimer's disease [4][6] Technology and Mechanism - Sabirnetug is co-formulated with Halozyme's ENHANZE® drug delivery technology, which enhances subcutaneous delivery by allowing larger volumes to be administered [3][7] - The drug targets toxic soluble AβOs, which are believed to play a critical role in the neurodegenerative process of Alzheimer's disease [5][9] Company Overview - Acumen Pharmaceuticals is focused on developing therapies targeting soluble AβOs for Alzheimer's disease and is headquartered in Newton, Massachusetts [9]